ArticleJournal of translational medicine2018
Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- GV21 enables ultrasound molecular imaging of tumor cell-associated VEGFR2 for early therapy assessment.Materials today. Bio · 2026Article
- Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report.Frontiers in oncology · 2026Article
- Long-term survival in metastatic gastric cancer patient with Apatinib plus S-1 maintenance treatment following first-line chemotherapy-case report.Frontiers in oncology · 2024Article
- Apatinib enhances chemosensitivity of ABT-199 in diffuse large B-cell lymphoma.Molecular oncology · 2022Article
- Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study.Frontiers in oncology · 2022Article
- Immune cell profiling in atherosclerosis: role in research and precision medicine.Nature reviews. Cardiology · 2022Review
- Therapeutic Interaction of Apatinib and Chidamide in T-Cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis.Journal of personalized medicine · 2021Article
- Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL-17 via the Bax/Bcl-2 signaling pathway.Experimental and therapeutic medicine · 2021Article
- Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer.Clinical and translational medicine · 2021Article
- Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications.Frontiers in oncology · 2021Review
- Apatinib as an alternative therapy for advanced hepatocellular carcinoma.World journal of hepatology · 2020Review
- Spontaneous and Induced Animal Models for Cancer Research.Diagnostics (Basel, Switzerland) · 2020Review
- Huai Qi Huang Potentiates Dexamethasone-Mediated Lethality in Acute Lymphoblastic Leukemia Cells by Upregulating Glucocorticoid Receptor α.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway.Cancer cell international · 2020Article
- Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal MesotheliomaFrontiers in oncology · 2020Article
- Qigesan reduces the motility of esophageal cancer cells via inhibiting Gas6/Axl and NF-κB expression.Bioscience reports · 2019Article
- Role of Autophagy and Apoptosis in Acute Lymphoblastic Leukemia.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundAcute lymphoblastic leukemia (ALL) is a clonal malignant disorder characterized by an uncontrolled proliferation of immature B or T lymphocytes. Extensive studies have suggested an involvement of angiogenesis signaling in ALL progression and resistance to treatment. Thus, targeting angiogenesis with anti-angiogenic drugs may be a promising approach for ALL treatment. In this study, we investigated the effectiveness of Apatinib, a novel receptor tyrosine kinase inhibitor selectively targeting VEGFR-2 in ALL cells.
methodALL cell lines were treated with different concentration of Apatinib and then CCK8 assay, flow cytometry were used to determine the IC
resultsOur results showed that Apatinib significantly inhibited cell growth and promoted apoptosis in both B and T lineage ALL cell lines in a dose- and time-dependent manner. The IC
conclusionOur study indicates that Apatinib exerts its anti-leukemia effect by inducing apoptosis through suppressing the VEGFR2 signaling pathway, supporting a potential role for Apatinib in the treatment of ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.